全文获取类型
收费全文 | 6120篇 |
免费 | 415篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 38篇 |
儿科学 | 156篇 |
妇产科学 | 165篇 |
基础医学 | 738篇 |
口腔科学 | 101篇 |
临床医学 | 733篇 |
内科学 | 1326篇 |
皮肤病学 | 90篇 |
神经病学 | 545篇 |
特种医学 | 294篇 |
外科学 | 680篇 |
综合类 | 208篇 |
一般理论 | 2篇 |
预防医学 | 538篇 |
眼科学 | 93篇 |
药学 | 481篇 |
1篇 | |
中国医学 | 84篇 |
肿瘤学 | 287篇 |
出版年
2023年 | 27篇 |
2022年 | 58篇 |
2021年 | 147篇 |
2020年 | 90篇 |
2019年 | 121篇 |
2018年 | 140篇 |
2017年 | 106篇 |
2016年 | 119篇 |
2015年 | 159篇 |
2014年 | 204篇 |
2013年 | 264篇 |
2012年 | 415篇 |
2011年 | 413篇 |
2010年 | 256篇 |
2009年 | 228篇 |
2008年 | 336篇 |
2007年 | 310篇 |
2006年 | 321篇 |
2005年 | 330篇 |
2004年 | 298篇 |
2003年 | 257篇 |
2002年 | 242篇 |
2001年 | 89篇 |
2000年 | 70篇 |
1999年 | 61篇 |
1998年 | 77篇 |
1997年 | 78篇 |
1996年 | 73篇 |
1995年 | 74篇 |
1994年 | 73篇 |
1993年 | 48篇 |
1992年 | 37篇 |
1991年 | 35篇 |
1990年 | 37篇 |
1989年 | 55篇 |
1988年 | 48篇 |
1987年 | 45篇 |
1986年 | 44篇 |
1985年 | 29篇 |
1984年 | 30篇 |
1983年 | 30篇 |
1982年 | 22篇 |
1981年 | 28篇 |
1980年 | 22篇 |
1959年 | 35篇 |
1958年 | 59篇 |
1957年 | 88篇 |
1956年 | 45篇 |
1955年 | 75篇 |
1954年 | 67篇 |
排序方式: 共有6560条查询结果,搜索用时 31 毫秒
1.
2.
3.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
4.
5.
宫腹腔镜联合手术诊治不孕症150例分析 总被引:14,自引:0,他引:14
目的:探讨宫腹腔镜联合手术在诊治不孕症中的应用。方法:对150例不孕症患者行宫腹腔镜联合手术,对不孕症病因进行诊断,同时行治疗。结果:盆腔粘连和输卵管阻塞是不孕症的主要原因。子宫内膜息肉和正常盆腔占次要比例。子宫内膜异位症和多囊卵巢也是主要病因。150例同时行宫腹腔镜输卵管通液和各种疾病的治疗。联合手术后妊娠率为48.8%。结论:腹腔镜联合手术,在一次麻醉下,可以对不孕的原因全面评价和明确诊断,在诊断同时进行治疗,对不孕症的诊断和治疗有重大的意义,值得推广。 相似文献
6.
Gavin Wright 《ANZ journal of surgery》2005,75(11):952-952
7.
8.
9.
10.
Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. 总被引:1,自引:0,他引:1
Rosemary Masterson Tim D Hewitson Kristen Kelynack Marina Martic Laura Parry Ross Bathgate Ian Darby Gavin Becker 《Nephrology, dialysis, transplantation》2004,19(3):544-552
BACKGROUND: Renal fibroblasts are important effector cells in tubulointerstitial fibrosis, with experimental antifibrotic strategies focusing on the functional down-regulation of these cells. Several experimental models of fibrosis have provided evidence for the effectiveness of the polypeptide hormone relaxin as a potential antifibrotic agent. This study was conducted to further elucidate the antifibrotic mechanisms of relaxin on renal fibroblasts in vitro. METHODS: Rat cortical fibroblasts were obtained from outgrowth culture of renal tissue isolated from kidneys 3 days post-unilateral ureteric obstruction and constituted 100% of cells studied. A relaxin radio-receptor assay was used to establish binding of relaxin to renal fibroblasts in vitro. Functional studies then examined the effects of H2 relaxin (0, 1, 10 and 100 ng/ml) on fibroblast kinetics, expression of alpha-smooth muscle actin (alpha-SMA), total collagen synthesis, collagenase production and collagen-I lattice contraction. CTGF mRNA expression was also measured by northern analysis. RESULTS: H2 relaxin bound with high affinity to rat renal fibroblasts, but receptor numbers were low. Consistent with its previously reported bimodal effect, transforming growth factor (TGF-beta 1) reduced fibroblast proliferation, an effect abrogated by H2 relaxin. Fibroblasts exposed to H2 relaxin (100 ng/ml) for 24 h demonstrated decreased immunostaining for alpha-SMA and reduced alpha-SMA protein expression compared with controls. There was a trend for a relaxin-mediated reduction in total collagen synthesis and alpha 1(I) mRNA expression with large dose-related increases in collagenase protein expression being observed. TGF-beta 1-stimulated collagen-I lattice contraction was significantly inhibited following co-incubation with 100 ng/ml relaxin. Incremental doses of H2 relaxin had no significant effect on CTGF mRNA expression. CONCLUSIONS: The findings of this study suggest that the antifibrotic effects of relaxin involve down-regulation of fibroblast activity, increase in collagenase synthesis and restructuring of collagen-I lattices, which are consistent with its known physiological role of matrix remodelling. Although there appears to be an interaction between TGF-beta 1 and H2 relaxin, this does not appear to involve a reduction in CTGF mRNA expression. 相似文献